FindTrial
Sign In

The ED50 and ED95 of alfentanil combined with remazolam for day abortion surgery

The ED50 and ED95 of alfentanil combined with remazolam for day abortion surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049513
Enrollment
Unknown
Registered
2021-08-02
Start date
2021-04-08
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Outpatient abortion surgery

Interventions

R5 group:Remazolam 0.3mg/kg+ 18.6ug/kg Alfentanil
R6 group:Remazolam 0.3mg/kg+ 22.2ug/kg Alfentanil
R1 group:Remazolam 0.3mg/kg+ 9ug/kg Alfentanil
R2 group:Remazolam 0.3mg/kg+ 10.8ug/kg Alfentanil
R3 group:Remazolam 0.3mg/kg+ 13ug/kg Alfentanil
R4 group:Remazolam 0.3mg/kg+ 15.5ug/kg Alfentanil

Sponsors

Yuhang District Women and Children Care Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Agree to this study; age 18-40 years old; BMI18-28; ASAI grade-II female patients; within 60 days of pregnancy; planned to undergo painless artificial abortion surgery

Exclusion criteria

Exclusion criteria: Severe cardiovascular and cerebrovascular diseases; hepatitis; kidney disease, severe anemia and malnutrition; history of endocrine disease; history of chronic pain; history of mental illness or psychotropic drug dependence, patients who are allergic to alfentanil.

Design outcomes

Primary

MeasureTime frame
Body movement response;Drug dosage;—

Secondary

MeasureTime frame
Waking time;Vital signs;—

Countries

China

Contacts

Public ContactLinda Jin

Yuhang District Women and Children Care Hospital

littledandan_927@sina.com+86 15967106092

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026